Jane P F Bai, Fatemeh Beigmohammadi, Morgan Craig, Mackenzie Dalton, Rajat Desikan, Terry Easlick, Sonia Gazeau, Jane Heffernan, Anna Kirpichnikova, Pranesh Padmanabhan, Jeffrey R Sachs, Anna Sher, David Skibinski, Amber M Smith
This perspective paper illustrates how model-informed vaccine development (MIVD) impacts vaccine discovery and development decisions, saving time and resources. It discusses the benefits of mechanistic and other mathematical models within MIVD. We outline key applications, opportunities, challenges, and future steps for MIVD as a call for the continued integration of mathematical modelling during vaccine development.